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SIRT1 is the mammalian ortholog of silent information 
regulator 2 (Sir2) found in Saccharomyces cerevisiae 
and functions as a NAD
+-dependent deacetylase. SIRT1 
appears to promote healthy aging and is implicated in 
the prevention of many age-related pathologies [1]. At 
the cellular level, SIRT1 controls lipid and glucose 
homeostasis, DNA repair and apoptosis, circadian 
clocks, inflammation and mitochondrial biogenesis. The 
biological effects of SIRT1 are mediated by its ability to 
deacetylate several key transcription factors such as 
Peroxisome proliferator-activated receptor-ϒ co-
activator 1 alpha (PGC-1α), p53, and FOXO proteins 
[2]. 
 
For many years there has been interest in characterizing 
sirtuin-activating compounds  (STACs)  that  can  modu- 
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late the ability of SIRT1 to deacetylate substrate 
proteins. These compounds would have the potential of 
reducing the incidence of multiple age-related diseases. 
Resveratrol and a series of chemically unrelated 
synthetic molecules have been described as potential 
STACs [3-7]. The original reports demonstrated 
activation by using an enzyme assay that contained a 
fluorescently labeled peptide substrate. However, the 
validity of these findings was challenged when others 
demonstrated that activation was dependent on the 
presence of the fluorophore on the substrate. Multiple 
studies followed, some in favor and some against [8-
10]. However, two new studies, one by Hubbard et al., 
(2013) in this month’s issue of Science and a second 
one by Lakshminarasimhan et al., (2013) in recent of 
Aging, appear to elegantly resolve this controversy.  
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Figure 1. Model of allosteric activation of SIRT1 by sirtuin activating compounds (STACs). (A) SIRT1 acting on a substrate with
a hydrophobic signature (yellow) in the absence of a STAC. (B) Binding of a STAC alters the N‐terminal structure of SIRT1 but
the absence of hydrophobic residues C‐terminal to the acetyl‐lysine on the substrate prevents activation by STACs. (C) The
aminomethycoumarin  group  on  the  Fluor‐de‐Lys  peptide  substrate  mimics  hydrophobic  residues  of  natural  substrates,
facilitating activation by STACs. (D) Substrate contains hydrophobic residues C‐terminal to the acetyl‐lysine thus allowing
STAC‐induced activation. Mutation of E230 allows STACs to bind to SIRT1 but abolishes STAC‐mediated allosteric activation. 
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acetylome microarray system to determine whether 
natural deacetylation sites can respond to resveratrol-
dependent SIRT1 activation. After testing almost 7,000 
peptides, surprisingly, very few of them exhibited 
increased deacetylation in the presence of resveratrol. 
They found that deaceylation by SIRT1 was 
preferentially activated when the substrates contained 
large, mainly hydrophobic residues at several positions 
C-terminal to the acetyl-lysine. These results provided a 
clear potential explanation of why the Fluor-de-Lys 
fluorophore, which is bulky and hydrophobic, may 
replace the peptide chain immediately C-terminal to the 
acetyl-lysine, likely mimicking a natural hydrophobic 
residue. 
 
Indeed, Hubbard and colleagues provided strong 
support for such a model, and extended the above 
findings by demonstrating that a series of STACs, 
including the Sirtris compounds and resveratrol, directly 
activate SIRT1 through an allosteric mechanism. They 
first determined that the fluorophore caused activation 
only when it was directly adjacent (+1) to the acetyl-
lysine. Similar to the findings of Lakshminarasimhan et 
al., (2013) the fluorophore moieties were dispensable if 
replaced with naturally occurring hydrophobic amino 
acids. For instance, native peptide sequences of PGC-1α 
and FOXO3a supported activation by STACs which 
was dose-dependent and mediated through a lowering 
of peptide Km. When the aromatic or hydrophobic 
amino acids at position +1 or +6 of PGC-1α or +1 of 
FOXO3a were mutated to alanine, activation by STACs 
was blocked. To establish the mechanism of activation, 
they screened SIRT1 mutants that were unable to be 
activated by resveratrol. Substitution of a glutamate for 
lysine at position 230 in the structured N-terminal 
domain attenuated (or abolished) SIRT1 activation by 
117 chemically diverse STACs independent of the 
substrate. This residue is outside the catalytic site of 
SIRT1 and is highly conserved. Altering this residue did 
not reduce the basal catalytic activity of SIRT1 or 
significantly change the Vmax or Km of several 
substrates but rather specifically inhibited activation by 
STACs. Finally, they reconstituted SIRT1 KO 
myoblasts with wild-type or mutant SIRT1 and 
observed STAC-induced increases in mitochondrial 
mass and ATP content in wild-type-reconstituted but 
not mutant-expressing myoblasts, thus demonstrating 
that the effect of STACs on mitochondrial function is 
clearly SIRT1-dependent and direct.  This work 
elegantly describes a SIRT1-dependent mechanism of 
“assisted allosteric activation” for STACs, providing a 
putative molecular explanation for the previous 
controversy. 
The findings by both groups that only a small subset of 
SIRT1 substrates have increased deacetylation by 
SIRT1 in the presence of STACs is promising for future 
therapeutic intervention strategies, since the selectivity 
of STACs could be far more targeted than previously 
anticipated. For instance, the SIRT1 substrates PGC-1α 
and FOXO3a, but not p53, have hydrophobic residues 
needed for activation by STACs, thus one could 
envision that STACs would have a greater impact on 
cellular metabolism and less of an impact on p53 
stability and the cell cycle. This selectivity may allow 
the use of STACs in the treatment of SIRT1-dependent 
metabolic diseases while avoiding some of the adverse 
pro-oncogenic effects of p53 deacetylation and 
destabilization. 
 
Of course, full proof of such molecular mechanisms 
will only come from crystal structure analysis of SIRT1 
in the presence and absence of STACs, work that will 
also allow for the design of more efficacious and 
diversely targeted STACs.   It will be interesting to 
determine whether SIRT1 STACs or similarly 
structured compounds could influence other sirtuins. In 
this regard, glutamate 230 is not conserved in any of the 
other mammalian sirtuins, suggesting that the allosteric 
mechanism may work specifically for SIRT1. Overall, 
these studies provide solid new evidence for a 
molecular mechanism of action for these compounds, 
and likely set up the basis for hypothesis-driven 
pharmacological applications of these STACs in the 
near future.   
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